Who is sponsoring NCT00411684?

NCT00411684 is sponsored by HRA Pharma.

What condition does NCT00411684 study?

NCT00411684 studies Emergency Contraception.

What is the status of NCT00411684?

NCT00411684 is currently COMPLETED.

Last reviewed 2021-08-27 · How we verify

A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CDB-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Sex

NCT00411684 Phase 3 COMPLETED Results posted

The purpose of this study is to assess the safety and efficacy of CDB-2914 for preventing pregnancy when taken 3 to 5 days after unprotected sexual intercourse.

Details

Lead sponsor	HRA Pharma
Phase	Phase 3
Status	COMPLETED
Enrolment	1623
Start date	2006-11
Completion	2009-06-05

Conditions

Emergency Contraception

Interventions

CDB-2914

Primary outcomes

Pregnancy Rate — Up to 60 days after enrollment
A high sensitivity pregnancy test was performed at inclusion (between 48h and 120h after unprotected intercourse) and then until menses occured or up to 60 days if they did not, at the following time points: * 5-7 days after expected date of menses * 1 week later * every two week after

Countries

United States